NCT04846647|Completed
Study of the Inappropriate Secretion of FGF23 in Patients Followed in Hospital in a Context of Hypophosphatemia
IFEH
Loading search results
IFEH
Sponsor study identifier
Secondary identifiers
OTHER · 2021-A00284-37
observational
260
1 country
2
Study Start
October 5, 2021
Actual (reported)Primary Completion
April 25, 2022
Actual (reported)Study Completion
April 25, 2022
Actual (reported)The discovery of FGF23, the missing link in the long researched and finally found phosphate metabolism, marked a turning point in the understanding and physiopathology of specific hypophosphatemia. By inhibiting the renal reabsorption of phosphate and the production of calcitriol, FGF23 behaves like a hypophosphatemia hormone. Hypersecretion of FGF23 can occur in the case of genetic abnormalities (X-linked hypophosphatemic vitamin-resistant rickets, recessive or dominant hypophosphatemic rickets, McCune-Albright syndrome ...) or acquired abnormalities (oncogenic osteomalacia). Oncogenic osteomalacia can be induced by hyperproduction of FGF23 by benign tumours of mesenchymal origin. But more recently, several cases of malignant tumours secreting FGF23 have also been described (prostate, colon, breast, ovarian and lung cancers, pulmonary carcinoma, etc.)
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
April 25, 2022
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
April 13, 2021
Actual (reported)April 15, 2021
Actual (reported)October 5, 2021
Actual (reported)April 25, 2022
Actual (reported)April 25, 2022
Actual (reported)Evaluate the frequency of blood levels of FGF23 unsuitable for hypophosphatemia
Assessing the presence of a blood level of FGF23 considered unsuitable for hypophosphatemia
day 0
Investigate the relationship between blood levels of FGF23 and other biochemical parameters in hospital patients with hypophosphatemia..
Day 1
Investigate the relationship between blood levels of FGF23 and other biochemical parameters in hospital patients with hypophosphatemia.
day 1
Collection of additional blood volume (approximately 10 mL) during blood tests provided as part of the usual medical care.
Collection of additional blood volume (approximately 10 mL) during blood tests provided as part of the usual medical care.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Major patient, male or female with hypophosphatemia (\< 0.80 mmol/L), without immediate anteriority
Chu Clermont Ferrand
Clermont-Ferrand, 63003, France
Centre Jean Perrin
Clermont-Ferrand, France
Suvannasankha A, Tompkins DR, Edwards DF, Petyaykina KV, Crean CD, Fournier PG, Parker JM, Sandusky GE, Ichikawa S, Imel EA, Chirgwin JM. FGF23 is elevated in multiple myeloma and increases heparanase expression by tumor cells. Oncotarget. 2015 Aug 14;6(23):19647-60. doi: 10.18632/oncotarget.3794.
Imel EA, Biggin A, Schindeler A, Munns CF. FGF23, Hypophosphatemia, and Emerging Treatments. JBMR Plus. 2019 May 13;3(8):e10190. doi: 10.1002/jbm4.10190. eCollection 2019 Aug.
Damien BOUVIER
University Hospital, Clermont-Ferrand
260 participants (actual enrollment reported by the registry).
First Submitted
April 13, 2021
First Posted
April 15, 2021
Study Start
October 5, 2021
Actual (reported)Contact the study team to confirm eligibility.
Endo I, Fukumoto S, Ozono K, Namba N, Inoue D, Okazaki R, Yamauchi M, Sugimoto T, Minagawa M, Michigami T, Nagai M, Matsumoto T. Nationwide survey of fibroblast growth factor 23 (FGF23)-related hypophosphatemic diseases in Japan: prevalence, biochemical data and treatment. Endocr J. 2015;62(9):811-6. doi: 10.1507/endocrj.EJ15-0275. Epub 2015 Jul 1.
Primary Completion
April 25, 2022
Actual (reported)Study Completion
April 25, 2022
Actual (reported)Last Updated
May 11, 2023
Record last verified: 2023-05
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: